Codiak, Jazz to develop exosomes against tricky oncogenes

Codiak BioSciences Inc. (Cambridge, Mass.) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) partnered to develop exosome therapies for hard-to-treat cancers.

Jazz gains exclusive, worldwide rights to develop, manufacture and commercialize exosome candidates

Read the full 295 word article

User Sign In